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ABSTRACT
COMPARISON OF AN IN SITU DNA PROBE HYBRIDIZATION ASSAY AND 
A RAPID ENZYME IMMUNOASSAY WITH CELL CULTURE FOR THE 
DETECTION OF HERPES SIMPLEX VIRUS INFECTIONS
Denault, Jacquelyn S.
University of Dayton, 1994
Advisor: Dr. Robert Kearns
Rapid diagnosis of HSV is needed for better management of patients with HSV 
infections. HSV isolation by cell culture remains the standard method for 
diagnosis, despite the drawbacks associated with this test. The performance of an 
in situ DNA probe hybridization assay (HSVDISK) and a rapid enzyme 
immunoassay (Surecell) was evaluated in comparison to cell culture, which was 
considered to be 100% accurate in the detection of HSV in clinical specimens. Of 
154 specimens from both asymptomatic and symptomatic patients, 42 were tested 
by Surecell and cell culture, and 152 were tested by HSVDISK and cell culture. 
Based on cell culture results, incidence of herpetic infection in the patient 
population was 23/154 (14.9%). The sensitivity and specificity of the Surecell 
assay were 88.9% and 87.9%, and those of the HSVDISK assay were 90.9% and 
99.2%, respectively. The Surecell assay was an easy test to perform and was an 
excellent screening test for positives, especially since virus present in the patient
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specimen did not need to be active for detection. However, the Surecell assay did 
produce results that were difficult to read with respect to intensity of color for 
5/42 specimens. The HSVDISK assay required minimal prior experience with cell 
culture and was more compact and easier to work with than cell culture tubes. 
However, this assay may not detect HSV in specimens with low titer. For rapid 
diagnosis of an HSV infection, the 15 minute Surecell and 24 hour HSVDISK 
assays are an improvement on cell culture, but cell culture can detect HSV in 
specimens with low HSV titer, making it a more accurate detection method for
HSV infection.
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INTRODUCTION
Herpes simplex virus (HSV) infections are among the most common viral 
infections affecting humans world wide. These infections are caused by two 
genetically distinct viruses belonging to the alphavirinae subfamily of herpes 
viruses, herpes simplex virus type-1 (HSV-1) and herpes simplex virus type-2 
(HSV-2).
The anatomic site of HSV infection and the age and immune status of the 
host determine the duration, severity, and type of HSV infection caused (1). 
HSVs are capable of infecting most areas of the body (2, 3), however, in 
immunocompetent hosts these infections are most commonly localized to skin, 
mouth, pharynx, eyes, genitalia and brain. For immunosuppressed hosts HSV 
infection can result in extensive damage to dermal tissue and could even result in 
infection of visceral organs. The number of severe cases of HSV infection has 
increased during recent years due to the widespread use of immunosuppressive 
therapy in cancer and transplant patients and due to the increased number of 
persons with AIDS (4).
In order for a primary infection to be established, HSV must overcome 
host physical and chemical barriers (e.g intact skin and skin pH) as well as 
nonspecific defense mechanisms (e.g. phagocytic and natural killer (NK) cell
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activity). HSV infection may not, however, always lead to productive replication 
of virus and appearance of vesicular lesions. In fact the primary infection with 
HSV typically results in symptoms that are so mild that the individual only 
experiences a little discomfort (1, 5). In persons with genital HSV-2 infection, 
asymptomatic primary episodes occur because childhood exposure to HSV-1 has 
instituted partial immunity to HSV-2 (2, 5). Despite whether or not clinically 
apparent lesions occur during a primary episode, neural tissue underlying the 
original infection site usually becomes infected, resulting in establishment of latent 
HSV which may later be reactivated from this neural tissue to cause recurrent 
infection (2).
Acquired immunity has a role in limiting the severity of the HSV infection 
but cannot prevent establishment of latent HSV and thus cannot prevent future 
symptomatic recurrences of infection (6). Progeny HSVs are able to avoid 
destruction by humoral immune mechanisms by spreading directly from cell to cell 
by fusion of cell membranes, i.e., formation of syncytia (7). In this manner, HSVs 
may never contact the extracellular environment, where anti-HSV antibodies can 
bind to and neutralize the HSV directly or can coat the HSV so that it may be 
opsonized by a phagocyte.
HSVs can also evade some cellular immune mechanisms. Cytotoxic T- 
lymphocytes are able to bind to and kill infected cells that express HSV antigens
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and major histocompatibility complex (MHC) antigen on their cell surface (2). 
However, neuronal cells do not express the MHC antigen that is required for the 
cytotoxic T-lymphocyte to bind (2). Thus, latently infected neuronal cells cannot 
be destroyed by these lymphocytes.
Both HSV-1 and HSV-2 are the cause of genital and orofacial infections, 
and infections caused by each type are usually clinically indistinguishable.
Therefore both types of HSV are not exclusively associated with specific infection 
sites, presumably because HSV-1 and 2 share 50% DNA sequence homology (1). 
In the United States, most orofacial infections are caused by HSV-1 while 
approximately 85% of genital infections are caused by HSV-2 (8). In Japan, 
however, most genital herpes cases are caused by HSV-1 (9). Symptoms and 
duration of infection are similar for HSV-1 and 2 genital infections, though 
recurrences are more likely for type 2 infections (4, 6). Similarly, orofacial HSV-1 
infections recur more frequently than orofacial HSV-2 infections (6). HSV-1 also 
causes most eye and brain HSV infections. Infection of the brain usually results in 
herpes simplex encephalitis (HSE), which is one of the rarest and most serious 
diseases caused by HSV-1.
Genital herpes is the most common disease caused by HSV-2. This disease 
is most often sexually transmitted, though it can be transmitted by self-inoculation 
of virus from an oral or finger infection in immunosuppressed patients (4).
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Sexually transmitted HSV-2 infections may also be associated with rectal and 
perianal HSV infection, especially in immunosuppressed patients whose genital 
infection has spread and in people having rectal intercourse (4).
The most serious consequence of genital herpes infection in females is 
neonatal herpes. Infection in the neonate may occur before, during or after the 
time of delivery (10). Most infections are caused by contact with the mother’s 
infected genital secretions as the baby passes through the genital tract, though 
transplacental transmission, ascending infection following rupture of membranes 
and postpartum infection resulting from contact with relatives or health care 
workers has been known to occur (10, 11).
A rapid and sensitive technique is needed to detect HSV infection, as early 
treatment can prevent fatality in people with herpes simplex encephalitis (12) as 
well as disseminated disease in infected neonates and immunosuppressed patients 
(13), and may ensure that effective treatment is being given to patients with less 
severe infections. Current techniques are either difficult to perform, lack 
sensitivity and/or specificity or take too long for an accurate diagnosis (14-17).
The objectives of this research were to evaluate two diagnostic kits for 
HSV: one, a cell culture system (HSVDISK) that uses centrifugation to speed up 
the infection process and an HSV specific DNA probe for detection of HSV DNA
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in the cells; and the other, an enzyme immunoassay (Surecell) that uses HSV 
specific antibody to detect viral antigen in the patient specimen. To determine 
sensitivity, specificity, and the ability of the Surecell and HSVDISK tests to predict 
"true" HSV positives and negatives, the two tests were compared to viral isolation 
by cell culture, the "gold" standard method of detecting HSV (17). At the same 
time, each of the three tests were rated according to speed of HSV detection and 
the ease at which the test was performed.
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LITERATURE REVIEW
General Properties of HSV
HSV-1 and HSV-2 are classified in the alpha subfamily of herpes viruses 
(alphaherpesvirinae), which also includes varicella-zoster virus (18). The members 
of the alphaherpesvirinae share a number of characteristics. First of all, 
alphaherpesvirinae have linear, double-stranded DNA genomes which are 
packaged in an icosahedral capsid. In HSV-1 and 2, this capsid is surrounded by 
a protein and phospholipid tegument and an outerlying envelope that is derived 
from the host cell nuclear membrane (19). Viral glycoproteins are embedded in 
this envelope which function in viral attachment to the host cell membrane during 
the infection process.
The second common characteristic is that viruses belonging to this 
subfamily have short replication cycles (HSV replicates in approximately 18 hours) 
and the site of replication is the nucleus of the infected cell (20). HSV infection 
commences with attachment of the virus to receptors on the host cell followed by 
fusion of the viral envelope with the host cell membrane (1). This process allows 
the viral nucleocapsid to gain entry into the cell cytoplasm. The nucleocapsid is 
then transported to the cell nucleus and disassembled to release viral DNA. 
Subsequent expression of the viral genes needed for replication (alpha, beta, and
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gamma genes) then occurs in a sequential manner which is necessary for the 
formation of an infectious viral particle (20, 21). Alpha genes are expressed 
earliest, producing proteins that are used primarily to regulate expression of beta 
and gamma genes. Subsequently, the beta genes are expressed which code for 
regulatory proteins of gamma genes and for enzymes needed in replication of viral 
DNA The structural proteins that make up the viral particle are then coded for 
by the gamma genes, which are expressed last in the replication cycle. The 
replicated viral DNA is then packaged in the structural proteins coded for by the 
gamma genes and the resulting nucleocapsid acquires an envelope by budding 
through the host cell nuclear membrane (22). Progeny virions can then infect 
neighboring cells after they are transported via the endoplasmic reticulum and 
Golgi apparatus to the surface of the infected cell (23). Release of the progeny 
virions may or may not result in the lysis of the infected cell.
The life cycles of the various members of the alphaherpesvirinae subfamily 
differ in some aspects, but the common factor is that all these viruses have the 
ability to replicate in mucous membranes, skin, and neural tissues, enabling them 
to infect virtually any area of the body. In order to establish infection, it is 
important that the virus contact mucosal surfaces or abraded skin of the host and 
also survive host immune defenses (6). Replication of the virus in infected cells 
and spread of progeny virus to neighboring cells may then result in a primary 
symptomatic infection, which for members of alphaherpesvirinae classically
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manifests as vesicular lesions on the skin or mucosal surface surrounding the 
infected area. Primary infections with HSV, however, are most commonly 
asymptomatic or so mild that symptoms are barely noticeable (1, 5).
Another characteristic of the alphaherpesvirinae subfamily is that primary 
infection generally results in the establishment of latent virus in neural and dermal 
tissues which surround the site of primary infection. During latency, normal 
cellular activity continues to occur even in the presence of virus because the viral 
genome remains in a dormant phase of growth (non-replicating) in the nucleus of 
the infected cell (24-26). The virus may remain latent in an infected cell 
throughout an individual’s lifetime and may become spontaneously active in 
conditions of physical and emotional stress (6). Stressful factors such as excessive 
sunlight, hormonal changes, and trauma can trigger reactivations by derepressing 
latent viral genes (2), so that viral DNA replication and production of progeny 
viruses ensues. This reactivation may result in lytic infection in which progeny 
viruses are released by lysis of the infected cell or it may result in viral shedding in 
which viruses are released from the cell in a slow, controlled manner without 
lysing the infected cell (27). The released progeny can then infect neighboring 
cells or can be transported along neuronal axons to a new site where latent or 
active infection may be established (2). Symptoms produced during active 
recurrent infection at the same or a new site are generally less severe, more 
localized to the reinfection site, and are shorter in duration than the symptomatic
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primary episode (4, 5, 28). This is presumably due to immunity acquired as a 
result of primary infection (2). In most cases, reactivation of virus from latently 
infected cells does not lead to a symptomatic recurrence of infection, as these 
viruses are usually eliminated by host immune defense (29, 30). However if host 
immune defense is suppressed, as is the case for many cancer and AIDS patients 
or other persons on immunosuppressive therapy, these symptomatic recurrences 
are typically more frequent and severe (31). Thus host immune status primarily 
determines the frequency and severity of symptomatic recurrences (31). 
Unfortunately the physical and emotional stresses that trigger reactivations also 
suppress host defense mechanisms against the virus (2), so that during times of 
stress, even immunocompetent hosts are more likely to experience a symptomatic
recurrence.
Host Response to HSV
The various types of responses elicited by the host during an HSV infection 
include local, cellular, and humoral immune defense. HSV cannot normally 
penetrate intact skin, however, injured skin, mucous membranes, and conjunctiva 
are more susceptible (6). Nonspecific effectors such as macrophages, monocytes, 
and polymorphonuclear leukocytes (PMNs) are important in both the innate and 
acquired immune response to HSV infection (32). These cells can eliminate both 
extracellular and intracellular virus by phagocytosis, which can occur with or
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without the help of anti-HSV antibodies (33). Macrophages also act as antigen 
presenting cells (APCs) by processing HSV and presenting HSV antigen to a B- or 
T-lymphocyte so that the antigen’s effectiveness as an immunologic stimulus may 
be increased (34). APCs thus serve to prime the immune system so that immune 
response is much faster upon subsequent exposure to the antigen.
Initial encounter with HSV causes the proliferation and differentiation of 
specific B- and T-cell clones. Some of the progeny lymphocytes become the 
effector cells that produce the primary immune response, while others become 
memory cells which serve in eliciting a faster immune response during a secondary 
HSV exposure. B-cell derived effector cells are plasma cells which produce and 
secrete specific anti-HSV antibodies that can neutralize extracellular virus and 
bind to infected cells so that the infected cells may be opsonized (33). T-cell 
derived effector cells (T cytotoxic, helper, or suppressor cells) help eliminate 
extracellular HSV and HSV infected cells through the production of soluble 
factors called cytokines (35, 36). Contact of a primed T effector cell with HSV 
antigen stimulates the release of cytokines which can have several effects. The 
released cytokines can act to 1) neutralize extracellular HSV directly, 2) lyse an 
HSV infected cell by causing perforations in the host cell membrane, or 3) cause 
proliferation and migration of other effector cells (such as macrophages) at/to the 
site of infection (32). Various in vitro studies have shown that the production of 
the cytokines, interleukin-2 (35, 36), alpha-interferon (37), and interleukin-7 (38)
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by antigen activated T helper cells is necessary for cytotoxic T-lymphocyte lysing of 
HSV infected cells. Cytokines can also be produced by other immune cells such 
as macrophages, PMNs, and NK cells. The cytokines produced by these cells may 
act on the same type of cell or on other immune cells to ultimately produce an 
anti-HSV response. Interferon, for example, whether produced by macrophages 
or T-lymphocytes, causes pleiotropic effects on macrophages (32). In addition, 
exogenous alpha- and gamma- interferon appears to inhibit HSV-1 genes encoding 
early gene products in spleen macrophages of mice (39, 40). Thus interferon not 
only causes proliferation and migration of macrophages to the infected site but 
also is able to prevent replication of HSV-1 in infected spleen macrophages of 
mice. Indeed the role of cytokines in immune defense against herpes simplex 
viruses has not been fully elucidated.
In addition to effector cells, clones of memory B- and T-cells are produced 
as a result of the initial encounter with HSV. Upon subsequent exposure to HSV 
antigen, such as in the case of reactivated virus or exposure to another viral strain, 
these memory B- and T-cells produce a faster and more efficient immune 
response. This is accomplished by the immediate transformation of memory B 
cells into plasma cells that produce an increased amount of antibody and 
proliferate forming other identical plasma cells and/or other memory B-cells. A 
similar process occurs with the memory T-cells, with these cells producing T- 
helper, suppressor and cytotoxic cell clones.
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Host defense mechanisms against HSV are not capable of completely 
eliminating HSV from an infected body, making HSV infection a lifelong threat. 
Certain characteristics in the HSV life cycle enable HSVs to avoid destruction by 
certain humoral and cell-mediated immune activities. First, progeny HSVs may 
spread directly from cell to cell during the infection process, bypassing host 
defense mechanisms that are only able to eliminate extracellular virus (including 
destruction via antibody neutralization, and by opsonization and other phagocytic 
mechanism requiring extracellular virus) (7). Secondly, HSVs can avoid 
destruction by the complement cascade, a series of enzymes (C1-C9) found in 
blood serum that can sequentially bind to and lyse an infected cell by making a 
hole in the cell membrane. HSVs produce a C3-binding molecule, glycoprotein 
Cl, which can cause decay of the C3 convertases of the classical and alternative 
pathways of the complement cascade (41). Thus the complement cascade does 
not provide protection against HSVs that express surface glycoprotein Cl. HSV 
strains and HSV infected cells that do not express the glycoprotein Cl, however, 
are susceptible to complement mediated cell lysis and viral neutralization (42). 
Thirdly, HSVs remain latent in neural cells which are not able to be killed by 
cytotoxic mechanisms due to the inability of cytotoxic T-lymphocytes to recognize 
and bind to cells that don’t express MHC antigen (43). Despite the viruses ability 
to evade destruction by these methods, both humoral and cell-mediated immune 
mechanisms help to keep HSV infection localized and shorten the duration of 
infection (1). Thus viral replication is inhibited by humoral and cellular immunity,
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but these immune mechanisms cannot prevent establishment of latency or viral 
reactivation which may lead to recurrent infection.
Antibody-dependent cellular cytotoxic (ADCC) activities which use both
humoral and cellular immune mechanisms have also been shown to slow down
viral replication. ADCC involves the cytotoxic activity of natural killer (NK) cells 
or some other leukocytes. During this process, the infected cell is coated with 
anti-HSV antibodies which bind to the viral antigens expressed on the cell’s 
surface. NK cells have receptors that can bind the Fc portion of the antibodies, 
so that the NK cell may contact the infected cell. This contact triggers the release 
of proteins called perforins which destroy the infected cell by making holes in the 
cell membrane (44, 45).
Because of the numerous activities involved in controlling HSV infection, it
is hard to determine the relative contribution of humoral and cell-mediated
immune mechanisms (46). Most of what is known about cell mediated immunity 
(CMI), for instance, comes from animal and human tissue culture studies which 
may not accurately portray CMI in vivo (46). CMI does seems to be of chief 
importance in limiting infection and maintaining latency, since patients with 
depressed CMI, such as people with AIDS, chronic eczema, and cancer, have 
more frequent and severe infections (1, 13, 47). Reactivated virus is not removed 
as effectively in these patients as it is in immunocompetent or
13
agammaglobulinemic individuals (1, 6).
Clinical Scope of HSV infection
Based on seroepidemiologic data, HSV-1 infections have been shown to 
occur in 50-100 percent of adults, depending largely on socioeconomic status (4). 
HSV-1 infections in persons of lower socioeconomic status are more prevalent and 
generally occur at an earlier age (6). Since HSV-2 is usually acquired as a 
sexually transmitted disease, antibodies against HSV-2 don’t usually appear until 
after adolescence. Studies have shown anywhere from 0.3 to 22% of adults in the 
United States have anti-HSV-2 antibodies (6, 30, 48, 49). Prevalence of 
seropositivity depends on age, sex, race, socioeconomic status, and sexual history 
of the individual (30, 48, 49).
Most primary infections with HSV-1 are asymptomatic, but may be 
followed by recurring clinically active infections (1, 5). Gingivostomatitis and 
pharyngitis are the most common symptomatic primary HSV-1 infections, while 
herpes labialis, or cold sores, is the most common recurrent HSV-1 infection (1). 
Clinical symptoms of gingivostomatitis and pharyngitis include vesicular or 
ulcerative lesions of the oropharynx and face accompanied by fever, malaise, and 
irritability. Recurrent infections of this type are referred to as cold sores or fever 
blisters, and are typically milder and more localized. The primary infection most
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often occurs before the age of 5 (5), but since most of these infections are 
asymptomatic most people experience the recurrent infection (cold sores/fever 
blisters) without ever having gingivostomatitis.
Infection of the eye with HSV-1 is a common cause of corneal blindness 
(50, 51). Primary and recurrent eye infection typically result in 
keratoconjunctivitis which is characterized by lesions surrounding the eye. 
However, recurring infections may also result in the formation of dendritic ulcers. 
Recurrences involving corneal stroma can lead to loss or impairment of vision (50, 
51).
HSV-1 is responsible for most skin infections. Two common HSV skin 
infections include herpetic whitlow and eczema herpeticum. Herpetic whitlow is 
caused by inoculation of HSV into a cut or sore on the hand (52) which results in 
vesicular lesions on the fingers. This disease occurs primarily in health care 
workers and thumb sucking children (53, 54). Eczema herpeticum occurs most 
frequently in people with chronic skin disorders. This disease results from 
inoculation of virus into skin lesions associated with eczema, which produces large 
vesicular lesions at the site of infection. These lesions are often fragile and burst, 
leaving the skin unprotected (4). Infection in these patients may rapidly spread 
covering extensive areas of the skin and may even disseminate to visceral organs.
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Herpes simplex encephalitis (HSE) is the rarest and most serious disease 
caused by HSV-1. This disease occurs predominantly in patients aged 5-30 and 
over 50 and may be the result of primary infection or recurrent infection (55).
HSE results from transmission of virus from the periphery up the olfactory bulb to 
the brain or from reactivation of latent virus in nerve root ganglia with spread of 
infection to the brain (56). Fever, headache, neurological problems associated 
with temporal lobe, and other non-specific clinical symptoms make diagnosis of 
HSE difficult. Untreated mortality rate is over 70%, and even with antiviral 
therapy, neurologic sequelae usually occurs (4, 57).
The most common disease caused by HSV-2 is genital herpes. Over 
500,000 new cases of symptomatic primary genital herpes and over 10,000,000 
symptomatic recurrences occur yearly in the United States (30). Primary 
symptomatic episodes of genital herpes last an average of three weeks and are 
characterized by painful vesicular lesions covering the external genitalia, buttocks, 
cervix and urethra. These lesions may accompany dysuria, fever, headache, 
malaise, genital itching and discharge, and tender lymph nodes (1). Prior HSV-1 
infection seems to lend partial immunity to HSV-2 genital infections, as these 
patients have less frequent symptoms and faster healing with the primary episode 
(5). The highest incidence of primary symptomatic genital infection occurs in 
people age 20-30 (6).
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Aseptic meningitis may be associated with primary genital HSV infection. 
Though rare, HSV may ascend to the spinal cord, where further replication can 
lead to aseptic meningitis (58). The disease course is self-limiting, but since latent 
infection may be established, recurrences may occur (59).
The most serious consequence of genital herpes infection is neonatal 
herpes. Infection in the neonate may occur before, during, or after the time of 
delivery (10). Currently, cesarean section is recommended if active maternal 
infection is present, but most women who deliver infants who get HSV infections 
are asymptomatic at the time of delivery (60, 61). Not all infants who are exposed 
to the virus around the time of delivery will acquire a herpes infection (62, 63). 
Being born to a mother with primary genital infection poses the greatest risk to 
the infant (64). Half the infants born to a mother with primary infection will 
develop an HSV infection, while only 4% born to mothers with recurrent infection 
will develop infection (64). Moreover, infants born to a mother with a primary 
genital infection more often develop disseminated infection, while infants born to 
a mother with a recurrent infection typically only develop skin, eye, or mouth 
lesions or localized encephalitis (63, 65). These differences are probably due to 
immunity acquired transplacentally from the mother in infants born to mothers 
with recurrent infections (65, 66). Disseminated herpes usually presents as a 
sepsis-like illness with fever and perhaps even the appearance of skin, eye, or 
mouth lesions (62). Other complications such as necrosis of the liver and adrenal
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glands, thrombocytopenia, meningoencephalitis or pneumonia may develop (67). 
Incidence of infection has been estimated to range from 1 in 7500 to 1 in 30,000 
births (68). Of these infected neonates, approximately 65% will die (4, 57) and 
those that live will most likely develop severe neurologic sequelae (67). 
Unfortunately, reactivation of HSV-2 infection is more common in pregnant 
women than in other women (69) and at least 20% of pregnant women have had 
prior HSV-2 infection (10, 70).
Due to the increased number of AIDS cases and the widespread 
administration of immunosuppressive therapy for transplants, cancer, and other 
diseases, the number of severe cases of HSV infection has increased during recent 
years (4). Patients undergoing such therapy can be subjected to frequent and 
severe reactivations of HSV infection. These recurrences of HSV infection may 
be associated with prolonged viral excretion and chronic lesions in these patients. 
These lesions can result in extensive tissue necrosis and though rare, may even 
lead to viremia and dissemination through multiple organs (28). Diseases such as 
meningoencephalitis, pneumonitis, hepatitis, coagulopathy, esophagitis, and 
proctitis may occur as a result of dissemination (1).
Therapy for HSV infections
Acyclovir, an antiviral therapeutic agent, is typically administered for both
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immunocompetent and immunosuppressed patients (13, 71). Treatment of 
immunosuppressed patients is usually started at first sign of HSV infection, even 
without culture confirmation of infection (13). Early treatment is imperative in 
these patients as HSV infection can be life threatening. Persons with AIDS 
however may develop resistance to acyclovir (13, 72). Vidarabine is an effective 
alternative to acyclovir therapy, however, this drug is not as efficient as acyclovir 
in fighting mucocutaneous HSV infection (73).
Laboratory Detection of HSV infections
The discovery of effective anti-HSV drugs has prompted the need for more 
rapid and sensitive HSV diagnostic tests in recent years. Early diagnosis and 
treatment ensures better patient prognosis, puts the patient at ease to receive 
reliable information on management and prognosis, ensures the doctor that proper 
treatment is being given, and decreases cost of health care by limiting patient 
hospital stay and eliminating the expense associated with unnecessary testing and 
treatment. HSV tests currently available to clinical laboratories either lack 
sensitivity or specificity, are tedious to perform, or take too long for an accurate 
diagnosis.
The most common methods for diagnosing herpes presently include viral 
isolation by cell culture, detection of HSV antigens by a variety of immunologic
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techniques such as enzyme-linked immunosorbent assays, enzyme immunoassays, 
immunoperoxidase staining, and immunofluorescence staining, and demonstration 
of amplified or non-amplified HSV DNA using various DNA hybridization 
methods (14, 16, 17).
Virus isolation by cell culture used with another method for confirmation of 
HSV-caused cytopathic effect (CPE) is the most sensitive, specific and widely used 
technique to date (74). Immunofluorescence staining is most commonly used to 
confirm HSV-caused CPE, however other confirmation techniques such as 
immunoperoxidase staining, ELISAs, EIAs, or DNA probe hybridization may be 
used. Even though cell culture is still considered the "gold standard" for HSV 
detection, this method often takes too long to detect infection, requires expertise, 
and may be affected by toxic components in the patient specimen. CPE takes an 
average of three days and may take as long as eight days to appear if low numbers 
of the virus are present (14, 17). A more rapid diagnosis is needed to test 
pregnant women near delivery for asymptomatic shedding of the virus (10), to 
ensure rapid treatment of neonates, immunocompromised patients, and persons 
with HSE for whom dissemination of HSV infection may be fatal (31, 60, 75), and 
to ensure that proper treatment is being given in cases where treatment has been 
initiated without clinical confirmation of the infection as being caused by HSV.
Cell culture also requires technical expertise for recognition of CPE and 
maintenance of the culture (74, 76). The expert must be trained in distinguishing
20
CPE caused by HSV and CPE caused by other viruses in order to perform the 
appropriate confirmation test. As a result of this, many hospitals and clinics send 
the clinical specimens to a virological laboratory for expert recognition of CPE, 
further delaying detection of the disease because of transport time. Another 
problem with cell culture is that toxic components in the specimen may also cause 
cell deterioration after a three to ten day incubation period (14, 76), making 
microscopic examination of the cells for CPE caused by HSV hard to interpret. 
Corey reported four cases in which toxic components in the rectal specimens of 
infants caused false positives in cell culture (14). The infants were immediately 
hospitalized and treated for HSV infection costing the hospital 10,000 dollars per 
infant, only to find out that repeat specimens taken from the infants were negative 
(14). Confirmation of HSV CPE by using a technique such as
immunofluorescence staining of cells has reduced the chance of this occurring, 
however some labs still rely on cell culture alone to determine infection by the 
virus. Though cell culture used in conjunction with an immunologic confirmation 
technique is currently the most accurate and widely used technique today, a more 
rapid, inexpensive, and more easily managed technique would be beneficial to the 
patient and hospital or clinic. Moreover, cell culture detection of HSV is not 
practical for small community hospitals or clinics that receive only a small number 
of patient specimens to be tested for herpes, as cell culture can be expensive and 
laborious to maintain. Many of these hospitals or clinics only receive a few 
specimens per week if any and staffing is not appropriate to perform such testing.
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Immunofluorescence, immunoperoxidase staining, immunoassays such as 
ELISA and EIA, and DNA hybridization techniques can be used alone (without 
cell culture) for detecting HSV in clinical specimens (14, 16). The main advantage 
of these techniques is that they are generally much faster and easier than HSV 
isolation by cell culture, but when used alone, these tests have generally shown 
lower sensitivities and specificities than cell culture (14, 15). Studies involving 
direct immunoperoxidase staining of specimens scraped from lesions have shown 
sensitivities of about 80% in comparison to cell culture used without a 
confirmation test (77-80). Because of the low sensitivity associated with direct 
immunoperoxidase staining of specimens, immunoperoxidase staining is generally 
only used to verily HSV isolates from cell culture (77, 80, 81). Another problem 
with this technique being used alone to directly detect HSV in the patient 
specimen is that a negative result is reliable only if the sample specimen contains 
intact cells. Schmidt and coworkers reported that out of 180 specimens, 23 
contained insufficient cells to permit valid interpretation of results (77). Thus the 
laboratory must confirm the adequacy of the specimen before processing it and 
specimens must be reacquired if they are unsatisfactory (77). Kits that combine 
cell culture with immunoperoxidase staining for the detection of HSV have found 
staining of cells at 48 hours to be less sensitive than standard cell culturing 
confirmed by immunofluorescence staining (82-85). Immunofluorescence and 
immunoperoxidase staining have, however, exhibited similar sensitivities in 
confirming an HSV isolate after CPE was observed in cell culture (77, 82).
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Sensitivities of ELISAs and EIAs range from 35 to 100% of that obtained 
by cell culture, depending on whether the CPE in cell culture is confirmed by 
another immunologic method (86-95). Specificities of immunoassays have been 
nearly equivalent however to those of cell culture (86-89, 94-96). The fact that 
results can be obtained in a few minutes to up to six hours using immunoassays 
warrants the use of these techniques for emergency diagnosis in case of suspected 
neonatal infection or infection in the immunocompromised (14, 86). However 
since this technique involves detection of viral antigen, a positive result is not 
necessarily synonymous with active infection of HSV (88), and false positives can 
sometimes occur due to non-specific binding of antibody (88, 94). At the present 
time, EIAs and ELISAs are most commonly used in combination with viral 
isolation by cell culture to verify a positive or negative result (89, 94, 97), or as a 
screening test for positives (89, 95) since specimens producing negative 
ELISA/EIA results are usually tested by cell culture as a backup.
A number of reports have shown immunofluorescence staining to be a less 
sensitive method than viral isolation by cell culture (98-103), although this method 
seems to be ideal for confirmation of HSV isolated by cell culture (104). In a 
long term study comparing immunofluorescence staining with monoclonal 
antibodies to viral isolation by cell culture in patients with recurrent genital 
herpes, Lafferty and coworkers (100) reported an overall sensitivity and specificity 
of 74 and 83%, respectively, in comparison to when both cell culture and
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immunofluorescence staining were used. However viral isolation by cell culture 
and the immunofluorescence staining technique when used alone had similar 
sensitivities (53 and 51%, respectively) for the initial sample received from the 
patient (100). Thus to maximize laboratory confirmation of HSV infection on a 
single visit by a patient, Lafferty and coworkers suggest that using just 
immunofluorescence staining or viral isolation by cell culture is not sufficient 
(100). In a similar experiment by Pouletty and coworkers (101), 
immunofluorescence assays using monoclonal antibodies were performed on 652 
specimens directly. This method showed a sensitivity of 84.6% in comparison to 
viral isolation by cell culture, however, for one patient, only one of three
specimens gave a positive result (101). Numerous investigators have suggested
that these false negatives may be due to the quality of the specimen sample (98,
100-102). Nerurkar reported problems in distinguishing negatives from positives
when a specimen smear was dried or stored too long before staining and when
nonspecific intense staining of debris in the specimen cells occurred (102). Thus
in addition to the decreased sensitivity of this method in comparison to cell culture
with confirmatory immunofluorescence staining, specimen quality and preparation
may be a hindrance in obtaining a correct positive or negative result. Although
immunologic methods used in conjunction with virus isolation by cell culture seems
to be the most sensitive and rapid way of obtaining an accurate result, the
ultimate goal for HSV diagnosis is to have a single test that is rapid, sensitive, 
reliable, simple and inexpensive.
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HSV infection may also be detected by demonstration of nonamplified 
HSV DNA using DNA probe hybridization. Probes can be labeled with enzyme 
or radioisotope and are usually added to the specimen sample directly (105-107). 
Using DNA probe hybridization has proven to be very rapid and convenient, 
however, the sensitivity and specificity of the probes used thus far to detect HSV 
DNA in a specimen seem to vary greatly and thus produce unpredictable results 
(105-107). In one experiment by Langerberg and coworkers (105), the sensitivity 
and specificity of a test using a biotinylated HSV DNA probe was compared to 
viral isolation by cell culture with immunofluorescence staining confirmation. The 
sensitivity and specificity of the test for detecting HSV was determined to be 92% 
and 63% to that of cell culture, respectively. Similarly, Fung and coworkers (106) 
reported a sensitivity of only 71.4% and a specificity of 90.6% for a biotinylated 
probe in comparison with cell culture used with immunofluorescence staining 
confirmation. The disparity in these results may be indicative of the 
unpredictability of this method. Furthermore Langenberg and coworkers (105) 
reported that the sensitivity of this method dropped to 57% that of cell culture 
with IF staining if a specimen of less than 20 cells was evaluated. Apparently, the 
sensitivity of the HSV DNA probe decreases dramatically at low virus 
concentrations (106). Another drawback to this method is that some DNA probes 
exhibit non-specific cytoplasmic binding (106, 107) when added directly to patient 
specimens, and thus may give a false positive reading. Fung and coworkers found 
that 27.2% of the specimens tested exhibited non-specific cytoplasmic staining with
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an HSV DNA probe (106). Because of the unpredictable sensitivity and 
specificity of these DNA hybridization tests, they have thus far only been used in 
conjunction with viral isolation by cell culture in determining if a patient is
infected with HSV.
More recently, probes have been used to detect amplified sequences of 
HSV DNA in the patient specimen directly using polymerase chain reaction 
(PCR), however, current problems with PCR such as carry-over of amplified 
products and requirement of specimen purity (16) make it hard to predict when 
this test will be able to be performed routinely in the clinical laboratory (15). 
Studies that have used this technique to determine the presence of HSV in clinical 
specimens generally report an equal or higher sensitivity for PCR as compared to 
cell culture (108-112), however, some of the results regarding patients whose 
specimens were positive by PCR but negative by cell culture weren’t conclusive as 
to whether the patient was experiencing an active infection (108, 111). Methods 
that use cell culture for the detection of HSV have an advantage in that only 
actively infecting virus will be detected. At the present time there is no clinically 
available PCR technique that can distinguish between a latent and an active HSV 
infection (16); previous studies using PCR to detect HSV have made diagnosis of 
active or latent infection based on the clinical status of the patient (16, 108, 110).
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Study Method
In this research two currently available kits, Diagnostic Hybrids 
HSVDISK™ and Kodak’s Surecell, were evaluated and compared to results with 
cell culture for detection of HSV in clinical specimens. Diagnostic Hybrid’s 
HSVDISK is a test kit for the culture and detection of HSV by in situ DNA probe 
hybridization. This method combines amplification of viruses by cell culture and 
detection of the viruses using in situ DNA probe hybridization after only 24 hours 
as compared to a 1-8 day diagnosis when using standard cell culture. This method 
has one advantage over other DNA probe hybridization methods in that viral 
numbers are amplified before detection, so clinical specimens containing only a 
few intact cells are not a concern. The 24-well cell culture trays are easier to 
handle than individual cell culture shell vials. The number of wells containing cell 
monolayers can also be varied according to the needs of the hospital or clinic.
Thus as many as 11 patient specimens can be tested on one tray. Kodak’s 
Surecell is a monoclonal antibody-based enzyme immunoassay that detects HSV 
antigen from patient specimen in under fifteen minutes, making it an appealing 
rapid test in cases where quick confirmation of HSV infection is needed. Since 
the Surecell assay detects HSV antigen, active HSV need not be present in patient 
specimen in order for a positive result to be obtained. The Surecell assay would 
thus be particularly useful in detecting HSV in late stage lesions which 
characteristically contain low titers of HSV. The Surecell test tray comes with
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built-in positive and negative control wells and accommodates only one patient 
specimen per tray. Thus the Surecell assay would be most appealing to hospitals, 
clinics, and doctor’s offices that rarely receive clinical specimens to be tested for
HSV.
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MATERIALS AND METHODS
Specimen Collection
Specimens were obtained from both asymptomatic and symptomatic 
patients from St. Elizabeth’s Medical Center, Dayton, Ohio. It was not known if 
the patients had ever experienced a prior HSV infection. All specimens from 
asymptomatic patients were collected from the hospital’s obstetrical-gynecological 
clinic. These patients were either pregnant or in their childbearing years.
A total of 154 specimens were analyzed, including 142 genital specimens 
and 12 specimens from other sites such as skin, esophagus, and abdomen. Of the 
154 patient specimens collected for the study, 40 were tested by standard cell 
culture, HSVDISK, and Surecell, 2 were tested by cell culture and Surecell only, 
and 112 were tested by cell culture and HSVDISK only. When available, age, sex, 
and clinical presentation of each patient was also recorded.
Specimens from active lesions were collected with sterile cotton swabs, and 
those from asymptomatic patients were collected by swabbing the cervix and/or 
vagina. All swabs collected were placed into viral transport medium consisting of 
approximately 1.8 mis of minimum essential medium with 10% fetal bovine serum 
and 10 /zg/ml gentamicin. A portion of each specimen was sent to a virological
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laboratory (Diagnostic Virology Services, Inc., Centerville, Ohio) to be tested by 
cell culture, while the other portion was reserved to perform the HSVDISK™ 
and/or the Surecell test(s) at St. Elizabeth microbiology lab. The swab from each 
specimen was reserved for use in the Surecell test. The HSVDISK™ test was 
performed within 48 hours of specimen receipt or the specimen was frozen at - 
70°C and tested at a later time. Surecell and cell culture tests were performed 
within 24 hours of specimen receipt.
Cell Culture Method
Cell culturing at the reference laboratory was performed by inoculation of 
the patient specimen onto triplicate African Green Monkey Kidney cells. The 
cells were then centrifuged to allow absorption of virus present in the patient 
specimen onto the cell monolayer and incubated at 37°C in 5% CO2. Cultures 
were observed daily for 10 days for CPE. If CPE did not occur within this time 
period, cultures were considered negative. Immunofluorescence staining of the 
cells was used to confirm CPE caused by HSV.
HSVDISK™ method
HSVDISK kits were obtained from Diagnostic Hybrids, Inc., Athens, Ohio. 
The HSVDISK kit includes 24-well culture plates containing African Green
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Monkey Kidney Cells (CV-1), replacement medium, blocking solution, fixative 
solution, wash solution, chromogenic substrate solution, and probe hybridization 
solution. Positive controls were not provided. The probe hybridization solution 
contains a single stranded HSV-1 and -2 specific DNA probe linked to alkaline 
phosphatase in a buffer solution containing 25% formamide. The probe is 2-kb in 
length and includes 800- and 1,200-bp Pstl discontiguous regions of DNA from 
HSV strain IF that are cloned in the M13mpl9 bacteriophage (113).
Cell culture plates containing African Green Monkey Kidney Cells (CV-1) 
were maintained using kit replacement medium consisting of minimum essential 
medium supplemented with 10% fetal bovine serum and 10 /zg/ml gentamicin.
Cell monolayers were inoculated with 0.2 ml of patient specimen eluate per well, 
centrifuged at 700 x g for 10 minutes at room temperature to allow absorption of 
virus to cell monolayers, and incubated at 35-37°C in a humidified 5% CO2 
atmosphere for 24 hours. One positive and one negative control well were 
included on each plate. HSV-2 strain G and HSV-1 strain F obtained from 
American Type Culture Collection (Rockville, Md.) were used as positive controls.
At 24 hours, cell monolayers were submerged in 95% ethanol for 5 minutes 
after which 0.25 ml of blocking solution consisting of neutralized triethanolamine 
containing 0.05% sodium azide was added to each well for 5 minutes to reduce 
nonspecific background staining. The cell monolayers were fixed and the DNA
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denatured with 0.25 ml of fixative solution containing ethanol and sodium 
hydroxide. Alkaline phosphatase labeled HSV DNA probe hybridization solution 
(0.25 ml) was added to each well and the plate incubated in a 45°C water bath for 
30 minutes. The plate was washed three times with wash solution made of 
phosphate buffered saline and incubated with wash solution for 10 minutes at 
45°C. To develop color, 0.25 ml chromogenic substrate solution containing 
dimethylformamide, bromochloroindolyl, and nitrotetrazolium blue was added to 
each well and the plate placed in a 45°C water bath for 60 minutes. The wells
were washed with distilled water and each well examined for stained cells at 40
and 100X using an inverted light microscope. A positive result was indicated by 
> 10 cells in the monolayer whose nuclei are stained purple.
Surecell method
Surecell kits were obtained from Eastman Kodak Company, Rochester, 
New York. The Surecell kit includes a test cell with three wells (negative control, 
positive control, and patient specimen well), extraction buffer, three wash 
solutions, peroxide solution, negative control conjugate, antibody conjugate, leuco 
dye solution, extraction tubes and filter tips.
The Surecell test is able to detect HSV-1 or -2 directly from patient swabs 
or in patient swabs placed in viral transport medium. All specimens in this study
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were tested after placement of the swab in viral transport medium. HSV-specific 
antigens, if present in the patient specimen, are extracted by placing the swab, 0.5 
ml of the viral transport medium, and 0.5 ml of extraction buffer into an
extraction tube. The swab was rotated for one minute in the extraction solution to
release HSV-specific antigens and then discarded. A filter tip was attached to the 
tube and equal aliquots of solution were filtered into the three test cell wells.
Each well contains one filter membrane and an underlying absorbent pad so as 
the filtrate is drained through the wells, any HSV-specific antigen present in the 
filtrate binds to the filter membrane present at the bottom of the well. To 
eliminate non-specific binding reactions, each of the three wells were rinsed with 
buffered wash solution followed by hydrogen peroxide solution. The negative 
control conjugate containing non-HSV specific monoclonal antibodies was then 
added to the negative control well and the HSV-specific monoclonal antibody 
conjugate was added to the positive control and patient wells. After five minutes, 
the wells were rinsed and a leuco dye solution was added to develop color. 
Presence of a uniform pink color in the patient and positive control wells, but not 
in the negative control well, indicated a positive result.
Statistical Analysis
Calculations of sensitivity, specificity, and positive and negative predictive 
values for the HSVDISK and Surecell assays were made in comparison to the
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standard cell culture method, which was assumed to be 100% accurate in the 
determination of whether a patient specimen was positive or negative. The
calculations were as follows:
Sensitivity = true positives______
true positives + false negatives
Specificity = true negatives______
true negatives + false positives
Positive Predictive Value = true positives 
all positives
Negative Predictive Value = true negatives 
all negatives
X 100
X 100
X 100
X 100
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RESULTS
HSV Detection in Clinical Specimens
One hundred fifty four specimens collected from patients of St. Elizabeth 
Medical Center were analyzed for presence of HSV. Of these, 131 were cervical 
and/or vaginal cultures, 11 were penis cultures, and 12 cultures were from other 
sites such as skin, esophagus, stomach and abdomen. Sixty-five specimens were 
taken from patients experiencing symptoms suggestive of an HSV infection 
(symptomatic), while 89 were from patients showing no signs of HSV infection 
(asymptomatic). All specimens taken from asymptomatic patients were cervical 
and/or vaginal cultures.
Of the 154 patient specimens collected for the study, 40 were tested by 
standard cell culture, HSVDISK, and Surecell, 2 were tested by cell culture and 
Surecell only, and 112 were tested by cell culture and HSVDISK only. To assess 
their overall performance for detecting HSV in clinical specimens, the results from 
the Surecell and HSVDISK assays were compared to standard cell culture, the 
"gold standard" method of detecting HSV. Table 1 shows the comparison of 
results obtained for the 152 specimens tested by the HSVDISK and cell culture 
assays, while Table 2 shows the comparison of results obtained for the 42 
specimens tested by the Surecell and cell culture assays. There was disagreement
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in results for 3/152 specimens tested by the HSVDISK and cell culture assays 
(Table 1) and for 5/42 specimens tested by the Surecell and cell culture assays 
(Table 2). Thus there was concordance in results for 98% of the specimens 
subjected to the HSVDISK and standard cell culture methods, whereas 88.0% of 
the results obtained by the Surecell method agreed with the results determined by
cell culture.
HSV was isolated by standard cell culture in 23 of the 154 specimens. 
Incidence of herpetic infection in the overall population based on standard cell 
culture analysis was thus 14.9%. Only one of the positives by cell culture came 
from an asymptomatic patient. The HSVDISK method detected herpes simplex 
virus in 21/152 and the Surecell method detected HSV in 12/42.
Performance of HSVDISK and Surecell
The sensitivity, specificity, positive and negative predictive values were
calculated to assess the effectiveness of the HSVDISK and Surecell tests in
detecting HSV in clinical specimens. Calculations of sensitivity, specificity, and 
positive and negative predictive values for the HSVDISK and Surecell assays were 
made in comparison to the standard cell culture method, which was assumed to be 
100% accurate in the determination of whether a patient specimen was positive or 
negative. Table 3 shows the sensitivity, specificity, positive and negative predictive
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values calculated for the HSVDISK and Surecell tests. Both the HSVDISK and
the Surecell tests exhibited similar sensitivities of detecting HSV (90.9% and 
88.9%, respectively), though the ability of the Surecell test to predict true positives 
was much lower (66.6%) than that for the HSVDISK test (95.2%). The 
HSVDISK test was 99.2% as specific as standard cell culture in detecting HSV in 
clinical specimens, whereas the specificity of the Surecell test was 87.9% that of
cell culture.
Detection times of each of the tests studied were also compared. Results 
could be reported for the Surecell assay within 15 minutes and for the HSVDISK 
assay in one day. Positive results by standard cell culture were reported between 
1 and 4 days. The average detection time for a positive result by standard cell 
culture was 2.2 days. Table 4 gives the times to detection for the positives by cell 
culture. 30.4% of cell culture positives were detected as positive in one day, 
65.2% were detected positive in 2 days, 82.6% were detected in three days, and 
100% were detected by the fourth day. Two specimens, a skin and an abdominal 
fluid specimen, were found positive by standard cell culture but negative by the 
HSVDISK assay. CPE was detected on day 2 for the skin specimen and on day 4 
for the abdominal fluid specimen. The abdominal fluid specimen was also found 
negative by the Surecell assay.
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Patient Population
Incidences of herpetic infection in the symptomatic and asymptomatic 
subpopulations were also calculated. Of the 65 patients (18 males, 52 females) 
who were known to be symptomatic, there was an overall incidence of active 
herpetic infection in the population of 22/65 (33.8%). This value is comparable to 
those found in similar symptomatic patient populations (96, 114). Only one of the 
89 asymptomatic, obstetrical/ gynecological patients tested positive for HSV by cell 
culture. Incidence of active herpetic infection in the asymptomatic population was
thus 1.1%.
Since most of the specimens obtained in this study came from genital sites, 
an assessment of the incidence of genital herpes infection and the ages at which 
the patients experienced the genital infection was also made. Of the 142 genital 
specimens, twenty were found positive by cell culture. The other three non-genital 
cell culture positives included a wound, an abdominal fluid, and a gastric fluid 
specimen. Eighteen of the 20 positive genital cultures were taken from females. 
All positive female genital specimens came from women between the ages of 14 
and 30, while the two positive male specimens came from 18 and 28 year old 
males. The mean age of persons experiencing a herpes genitalis infection as 
confirmed by cell culture was 20.6 +. 2.96 with an age range of 14-30. Two of 
these patients were known to have a history of herpes infection.
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Four of the genital cultures found positive were taken from symptomatic 
pregnant women. Symptoms in two of the women included hyperemesis 
gravidarium (excessive morning sickness) for the woman who was 21 weeks 
pregnant and vaginal drainage for the women who was 24 weeks pregnant. 
Herpetic lesions were observed at delivery in the two other cases. One of the 
women, who had a herpetic lesion on her right thigh, delivered prematurely 
because of ruptured membranes at 24 weeks. It was unknown if any of the infants 
were affected by neonatal herpes infection.
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DISCUSSION
The HSVDISK DNA probe assay exhibited a number of visually-distinct 
types of positive reactions depending on the extent of infection of the cell 
monolayer. In the majority of the clinical isolates, a positive reaction was 
determined by the observance of a focal cluster of cells with nuclei stained purple. 
These foci would most often be accompanied by signs of CPE (e.g., syncytia 
formation and holes in the cell monolayer). Some patient wells possessed as few 
as two purple foci, though results from specimens containing a high titer of virus 
showed considerable cell destruction and detachment. There was no problem in 
determining whether a patient result was positive or negative, despite the fact that 
some positives looked different than others. In addition, no background staining 
due to non-specificity of the probe or loss of purple stain due to high cellular 
toxicity occurred, as was previously reported (115).
In the Surecell EIA test, there were difficulties in interpreting a result when 
there was a low amount of or non-specific deposition of pink dye on the filter 
membrane. Instructions provided by Kodak suggest that a patient specimen is 
positive for the presence of HSV antigen if a uniform pink color in the patient 
well is greater than the color found in the negative control well. For 4 of the total 
42 specimens analyzed by this method, it was difficult to determine if the patient 
well a)was uniformly colored with the pink dye or b)was more pink than the
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negative control well. Two of the four were most likely false positive results, as 
the color in each patient well was very light pink and the cell culture assay and 
HSVDISK assay results were negative. The remaining two results agreed with the 
results obtained by the HSVDISK assay and the cell culture assay, despite the 
difficulty that was encountered in interpreting these results.
The cell culture and HSVDISK methods reported different results for three 
specimens, all of which came from symptomatic patients. One abdominal fluid 
specimen and one skin specimen were found to be negative by the HSVDISK 
assay but positive by standard cell culture. The abdominal fluid specimen found 
negative by HSVDISK was positive by cell culture on day 4. The four day 
detection period required by cell culture suggests that the HSVDISK result was 
most likely a false negative due to a low titer of infectious virus in the patient’s 
specimen. The Surecell result for this particular specimen, however, was also 
negative. Thus there is the possibility that the cell culture may have been 
contaminated by carryover of HSV, but such contaminations are not likely. 
Nevertheless, the HSVDISK assay was successful in detecting HSV in three other 
specimens that took 4 days for cell culture to detect.
The HSVDISK result for the skin specimen was most likely a false negative 
result also, as this specimen had been frozen for 17 days prior to HSVDISK 
testing and freezing specimens has been shown to decrease the number of
41
infective viruses in a sample (116). Ten other cell culture-positive patient 
specimens were frozen for 2-30 days prior to HSVDISK testing. Despite the 
possible decrease in titer, all ten of these specimens were found positive by
HSVDISK.
The HSVDISK method detected one positive result which was not detected 
by cell culture or by the Surecell assay. A total of five foci with stained cells were 
found in the two HSVDISK wells, indicating that the patient specimen probably 
contained a low HSV titer. This patient was experiencing genital blisters at the 
time the viral culture was taken. The attending physician suspected the infection 
was caused by yeast or HSV, however, no follow up information on the physician’s 
final diagnosis of the patient was obtained. Since both wells contained foci with 
stained cells, it is not likely that the patient wells were contaminated by carryover 
from the positive control, especially since the patient wells were not adjacent to 
the positive control well and no other wells on the plate were positive for HSV. 
The low titer of HSV present in the specimen may have been inactivated during 
transport to the virological lab, or the specimen may have produced such a low 
amount of CPE that it was not detected during screening.
Overall, the sensitivity, specificity, positive and negative predictive values 
for the HSVDISK system were close to that of cell culture. This result was 
expected as the only differences between these two assays are that l)the
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HSVDISK assay uses DNA probe hybridization instead of immunofluorescence 
staining to confirm an HSV isolate and that 2)the HSVDISK assay does not 
screen for CPE prior to performing a confirmatory test for HSV presence. The 
use of an HSV-specific DNA probe gives the HSVDISK assay the ability to detect 
HSV in the cell monolayers before the appearance of CPE. Thus all results can be 
reported in one day, since it is not necessary to wait for the appearance of HSV- 
caused CPE before the in situ DNA probe hybridization test is performed.
The Surecell and cell culture tests produced different results for five 
specimens. One of these results was the aforementioned abdominal specimen 
which yielded a negative result by Surecell and a positive result by standard cell 
culture. The other four discrepancies occurred with genital specimens from 
symptomatic patients. These specimens were found to be negative by standard 
cell culture and the HSVDISK assay but positive by the Surecell assay. Several 
reasons could account for the discrepancies. First, these four specimens may have 
been false positives in which case the antibody used in the Surecell test to detect 
viral antigen may have non-specifically bound to the filter membrane or to some 
other substance present in the patient specimen. Non-specific binding of antibody 
has been suspected to occur in other immunoassays (88, 94), nevertheless, the 
Surecell test formerly demonstrated a high specificity (98.9%) and positive 
predictive value (96.7%) in comparison to cell culture (89). Another reason for 
the four discrepancies may be that active virus originally present in the patient
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specimen was inactivated during transport, so that active infection of the cell 
monolayer was never established in the cell culture and HSVDISK tests. In such 
a case, viral antigen in the patient specimen would still have been detected by the 
Surecell assay. Loss of infectious HSV may have occurred as a result of improper 
collection or mishandling of the specimen prior to receipt in the hospital 
laboratory. If this occurred, the 66.6% positive predictive value calculated for the 
Surecell test would be falsely low. Loss of infectious HSV during transport most 
likely occurred in two of the four patient specimens producing discrepant 
HSVDISK and cell culture results, since both of these patients had a history of 
genital herpes infection and both were experiencing genital pain, drainage and 
lesions at the time the specimens were taken.
The Surecell test is only recommended for use either for confirmation of 
cell culture or screening for positives before cell culture is performed. For 37/42 
specimens, this assay was able to duplicate cell culture results, making it a rapid, 
easy, and accurate screening test for clinics, doctor’s offices and hospitals that 
normally send patient specimens to virological labs for cell culturing. The Surecell 
assay by itself, however, is not a reliable detector of HSV infection because 
patient results are sometimes hard to interpret and because false positive results 
may be produced by the assay. On the other hand, HSV present in the patient 
specimen need not be viable to be detected by the Surecell assay.
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Though cell culture with confirmation of HSV infection by 
immunofluorescence staining, EIA, ELISA, or immunoperoxidase staining is the 
most sensitive technique to date, cell culture still takes an average of 3 days before 
positive results can be reported to the physician (14, 17), and can take even longer 
(up to 14 days) to report an accurate negative result (74). The average time for 
isolating HSV in cell culture was 2.2 days and only 30.4% could be detected at 24 
hours. The HSVDISK result could be reported in one day and the Surecell result 
could be reported in approximately 15 minutes from specimen receipt. For 
hospitals such as St. Elizabeth Medical Center which do not have the proper 
equipment and/or personnel to perform cell culture, transport time of the 
specimen from the hospital lab to the virological lab where cell culturing will be 
performed delays reporting of results (usually by one day). Thus rapid and 
accurate tests such as the Surecell and HSVDISK assays could be attractive 
alternatives to cell culture testing.
One genital culture from an asymptomatic patient was found to be positive 
by the HSVDISK and cell culture assays. The patient specimen was found 
positive by cell culture at 4 days post-inoculation and only produced two foci of 
stained cells per well when tested by the HSVDISK assay. Thus the HSV titer in 
the patient specimen was most likely low, as would be expected from a person 
who was asymptomatically shedding HSV. Cell culturing and related techniques 
have in the past been shown to be poor predictors of asymptomatic genital
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shedding (10). The detection of HSV in the patient specimen was therefore an 
unanticipated occurrence. No information on whether the patient had a prior 
history of genital HSV infection was available.
No follow-up information was available on the status of the infants of the 
pregnant women who tested positive for herpes during pregnancy. Only two of 
these women had herpetic lesions at the time the culture was taken. Women will 
often times first discover they have a genital HSV-2 infection during pregnancy 
(117), because the fluctuations in hormone levels reactivate an HSV-2 infection 
contracted prior to pregnancy. Reactivations from the cervix or vagina are 
especially a problem when they occur at the time of delivery. If the patient 
experiences lesions at this time, it is recommended that the baby be taken by 
caesarean section. However, these reactivations of latent HSV do not always 
accompany symptoms that are noticeable to the doctor or that would lead the 
doctor to perform a caesarean section. During these times of asymptomatic 
shedding, the baby may inadvertently be exposed to the virus. Fifty percent of 
newborns exposed to HSV at or around the time of delivery will die, and the 
majority of those that live will develop sequelae such as mental retardation, 
seizures, microcephaly, retinal dysplasia, encephalitis, or meningitis.
Because there are currently no clinically available tests that are sufficiently 
rapid and accurate to predict asymptomatic shedding of HSV at the time of
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delivery, future research in the development of tests sensitive enough to detect 
such viral shedding is essential. PCR seems to be the most promising testing 
technique for the near future, though widespread use of PCR in clinical labs has 
not yet been instituted because of problems associated with purifying patient 
specimens (16). Past PCR studies have claimed the detection of asymptomatic 
viral shedding in women at delivery (109, 110). These studies have based their 
findings on the assumption that viral shedding can only originate from neuronal 
cells, and not from non-neuronal cells (such as the cervical or vaginal epithelium). 
Other researchers claim that these PCR studies do not distinguish between the 
amplification and detection of latent viral DNA and the DNA of viruses that have 
been shed from host cells (16). Whether HSV is capable of establishing and 
maintaining latency in non-neuronal tissue has long been a matter of debate (118, 
119). Most researchers, nevertheless, seem to support that latency can only be 
maintained in neuronal cells (1, 2, 109, 110), where latent HSV DNA can be 
harbored without being destroyed by immune cells.
Despite the controversy of whether current PCR techniques can detect 
asymptomatic viral shedding in pregnant women at delivery, PCR has proven to 
be as sensitive and more rapid than cell culture in determining if neonates are 
infected with HSV (110), in detecting HSV in the cerebrospinal fluid (CSF) of 
persons with HSE (112), and in screening patients for HSV infection (108, 111). 
For neonates with HSE, HSV is demonstrable in CSF by cell culture in an
47
estimated 25-30% with the infection (56). Brain biopsy has thus far been the most 
accurate predictor of HSE infection (56). In a 1991 study performed on seven 
neonates with HSV infection, PCR was able to detect HSV DNA in multiple 
serum samples of one of the neonates in which cell cultures were repeatedly 
negative (110). The high sensitivity and rapidity of the PCR assay for detecting 
HSV DNA may in the future make it a preferable technique to cell culturing. In 
addition, diagnosis of HSE by performing PCR on serum or CSF samples is a 
safer alternative than diagnosis made by brain biopsy.
Development of more sensitive, rapid and accurate HSV diagnostic 
techniques would not be necessary if effective vaccines were available. A number 
of points must be considered in the development of HSV vaccines (120). First, 
the vaccine should provide protection against viral replication in the epithelial cells 
of mucous membranes, otherwise the HSV could establish latency in surrounding 
neurons. Preventing infection of these epithelial cells by exogenous HSV could be 
accomplished by creating a vaccine that will stimulate a strong IgA response in the 
recipient.
Secondly, the immunity provided by the vaccine should be long lasting. 
Development of attenuated vaccines which can be reactivated from latently 
infected cells would be ideal for generating long lasting immunity. The safety of 
the vaccine for human usage must also be considered. Since HSVs have been
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implicated in oncogenesis, the use of live or inactivated HSV vaccines is highly 
undesirable. If not properly attenuated, these live vaccines could be the basis for 
symptomatic infections. Currently, however, vaccine research has been focused on 
the development of vaccines based on synthetic viral polypeptides, selective viral 
genes cloned into non-HSV vectors, and live genetically engineered HSV, since 
these vaccines have no transforming potential. None of the HSV vaccines that 
have been tested for therapeutic efficacy in humans have thus far been successful 
(121). However, some vaccines tested in animal models have been successful in 
providing protection against subsequent HSV exposures (122, 123). The course of 
HSV disease in animals and susceptibility of the animals to HSV infection differs 
in comparison to humans. Therefore success of vaccines in animal models does 
not necessarily indicate that these vaccines will be efficacious for human usage.
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CONCLUSION
Presently there is no single diagnostic assay that is rapid or sensitive 
enough to detect HSV in pregnant women near delivery, in immunocompromised 
patients, or in persons with suspected HSE. PCR appears to be the most 
promising rapid diagnostic technique for the future. Further refinements with this 
method could produce an HSV diagnostic test that is less cumbersome and more 
rapid than cell culture. Based on data acquired in this research, assays such as the 
Surecell and HSVDISK assays can, however, provide dependable alternatives to 
standard cell culture. The HSVDISK assay is a cell culture method that is 
compact, easy to work with and requires minimal prior experience with cell 
culture. The in situ DNA probe eliminates the need of daily cell culture screening 
for CPE and since cells are delivered weekly, there is no need for the 
maintenance of a cell culture line. In addition, results are easy to read and can be 
obtained in 24 hours. The HSVDISK assay, however, can only be used in a lab 
that has access to or is equipped with a laminar flow hood, centrifuge, humidified 
incubator, -70°C freezer (for freezing controls) and an inverted light microscope. 
Overall the HSVDISK assay produced results comparable to standard cell culture, 
making it a dependable alternative to the cell culture method.
The Surecell test is particularly appealing for hospitals, clinics, and doctor’s 
offices that cannot afford to maintain expensive cell culturing equipment and
SO
experienced staff. Since the test can be performed in less than 15 minutes, it is an 
excellent screening test for HSV, either directly from the swab or from swabs 
-placed in viral-transport-medium. One of the drawbacks with the Surecell assay is 
that the interpretation of the result is not always clear, especially if the specimen 
swab contains a low titer of HSV. Because the positives are not always evident, at 
least one swab (or excess viral transport medium) should be reserved for cell 
culturing if a negative result is obtained by the Surecell assay. Despite this 
drawback, the Surecell assay is easy to perform and requires no specialized 
equipment. The Surecell assay could also be used as a confirmatory technique for 
viral isolates from cell culture, since the assay only takes a few minutes to 
perform.
In conclusion the continual evaluation of HSV diagnostic tests provides a 
service to hospitals, clinics, and doctor’s offices that do not have the funding or 
the means to randomly try out various tests to see which is the most appropriate 
for their purposes. Moreover this research as well as other HSV research 
concerning cures, therapy, and prevention helps to a)provide more efficient 
patient care b)limit the prevalance of HSV infections and the significant morbidity 
and mortality associated with HSV infections and c)ease the psychosocial impact 
on persons with genital herpes.
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TABLE 1
Comparison of HSV detection by HSVDISK in situ DNA probe assay to HSV 
isolation by standard cell culture
Standard Cell Culture
HSVDISK
result No. No. positive No. negative
Positive 21 20 1
Negative 131 2 129
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TABLE 2
Comparison of HSV detection by Surecell enzyme immunoassay to HSV 
isolation by standard cell culture
Surecell
result No.
Standard Cell Culture
No. positive No. negative
Positive 12 8 4
Negative 30 1 29
S3
TABLE 3
Performance assessment of Surecell and HSVDISK test in comparison to
standard cell culture3
Test Sensitivity Specificity
Predictive Value
Positive Negative
HSVDISK” 20/22
(90.9%)d
129/130
(99.2%)
20/21
(95.2%)
129/131
(98.5%)
SurecelP 8/9
(88.9%)
23/33
(87.9%)
8/12
(66.6%)
29/30
(96.7%)
3 Sensitivity, specificity, and positive and negative predictive values were calculated 
according to equations found in the Materials and Methods 
b Total specimens analyzed: 152
c Total specimens analyzed: 42
d Percentages were in relation to cell culture which was considered to be 100% 
accurate in the determination of whether a patient specimen was positive or 
negative
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TABLE 4
Detection of HSV by cell culture at various times post-inoculation
Cell Culture Incubation3 No. HSV Positive (%)b
1 7 (30.4%)
2 8 (65.2%)
3 4 (82.6%)
4 4 (100.0%)
a Times listed do not take into account transport time from the hospital laboratory 
to the virological laboratory where cell culture testing was performed 
b A total of 23 patient specimens were positive by cell culture
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